Flatiron Data Supports Using Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Flatiron Data Supports Using Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
share Share

This Pfizer-sponsored study used de-identified data derived from the Flatiron Health Analytic Database in a retrospective observational study to demonstrate palbociclib (PAL) combined with an aromatase inhibitor (AI) is an effective first-line therapy for treating metastatic breast cancer.

 

Hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic/advanced breast cancer (HR+/HER2– MBC) is the most common form of metastatic breast cancer. HR+/HER2– MBC often shows poor clinical outcomes due to multiple organ involvement and highlights the need for better treatments. Given its poor prognosis, analysis of the efficacy of already approved treatments can help the clinical decision-making in patients with advanced breast cancer.

 



Flatiron is an oncology platform licensed to large oncology pharmaceutical companies that aggregates patient data from EHRs, lab and medical claims and matches it with patient trial data. The data originates from 2.4 million actively treated cancer patients in the U.S., which can be used to provide real-world evidence of patient outcomes in retrospective research. In the current study, real-world progression-free survival (rwPFS) and best tumor response (rwBTR) were assessed in 813 patients with HR+/HER2– MBC. The time from starting PAL+AI to death or disease progression was defined as rwPFS, whereas the treating clinician’s assessment of change in disease burden based on imaging was defined as rwBTR. 

 

About 86.5% of the patients started PAL at 125 mg/day, with 13.5% using lower doses. About 11% stopped use due to toxicity. PAL treatment at 125 mg/day was associated with improved outcomes compared to the lower doses. Both rwPFS and rwBTR rate improved in comparison to the lower doses (27.8 vs 18.6 months and (54.0% vs 40.4%, respectively). Thus these data show the benefit of the combined PAL+AI treatment at the starting dose of 125 mg/day in routine clinical practice to treat HR+/HER2– MBC.


For more Women's Health news Click here 


Source: Clinical Breast Cancer

 

«« AI Catches What Radiologists Miss on Breast Screening


How Good is the Evidence Informing Breast Cancer Clinical Practice Guidelines? »»

References:

Patt D et al. (2022) Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clinical Breast Cancer.


Published on : Mon, 9 May 2022



Related Articles
AI Catches What Radiologists Miss on Breast Screening

A large German study found that AI can accurately detect and localise breast cancers on screening exams missed by radiologists,... Read more

The UK National Institute for Health and Care Excellence (NICE) now endorses the use of Magtrace and Sentimag magnetic marker... Read more

New findings published in Cancer Epidemiology Biomarkers & Prevent show significant differences in the accuracy of diagnostic... Read more

Pfizer, metastatic breast cancer, Breast Cancer, Screening, Womens Health This Pfizer-sponsored study used de-identified data derived from the Flatiron Health Analytic Database in a retrospective observational study to demonstrate Palbociclib (PAL) combined with an aromatase inhibitor (AI) is an effective first-line therapy for

No comment


Please login to leave a comment...

Highlighted Products